To investigate the clinical applications of GP73 as an anti-angiogenic target in HCC, the 238 HCC patients treated with lenvatinib were included for the generation and validation of a serum GP73-based prognostic nomogram for determining the estimated survivals (Supplementary Results). This evidence concerns the gene GOLM1 and hepatocellular carcinoma.